On Friday, the White House’s Council of Economic Advisors (CEA), an agency within the Executive Office of the President, released a white paper titled “Reforming Biopharmaceutical Pricing at Home and Abroad.”
On Friday, the White House’s Council of Economic Advisors (CEA), an agency within the Executive Office of the President, released a white paper titled “Reforming Biopharmaceutical Pricing at Home and Abroad.” The paper says that an effort to bring down high drug costs must recognize that prices are sometimes artificially high in the United States.
The CEA writes that the Medicare Part D program “creates perverse incentives for plan sponsors and pharmacy benefit managers (PBMs) to generate formularies that favor high-price, high-rebate drugs” that speed patients through the early phases of the benefit structure. Solutions proposed by CEA to address the issue include requiring plans to share drug manufacturer discounts with patients, allowing plans to manage formularies, lowering co-pays for generics, and discouraging formulary design that speeds patients to the catastrophic coverage phase.
The paper also suggests moving Medicare Part B coverage into Medicare Part D, “where price-competition over drug prices is better structured,” and cutting physician payments for drugs that have few available sales data, to eliminate “the incentive of prescribing a high-priced drug.”
Furthermore, the CEA posits that, as regulation currently stands, most biosimilars will not be granted interchangeable designations, so competition for biosimilars will be limited. If the FDA finalizes its guidance on demonstrating interchangeability and “If these guidelines are relatively easy and inexpensive to adhere to, it could spur interchangeable applications and approvals, which could result in more effective competition with the reference biosimilar and lower prices," according to the white paper.
Also of note is the paper’s contention that drug makers’ returns on investment for developing drugs are “unfairly low” because many governments negotiate drug prices directly with manufactures. “Pharmaceutical innovators—and foreign governments—across the world rely on America’s patients and taxpayers to finance critical research and development,” said the paper’s authors, who contend that the United States must limit “free-riding abroad.”
While President Trump has previously suggested using some of the same tactics employed in overseas markets to drive down drug prices—including negotiating drug prices for Medicare directly with drug makers—the paper does not propose such an approach.
The not-for-profit group Knowledge Economy International took issue with the paper, saying in its response that, “On the lack of competition for biosimilars, the report ignores the most important measure, which is to mandate greater access to manufacturing know-how and materials, in order to reduce the costs and time of entry for competitors.”
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
The 6 Key Policy Factors to Ensure Biosimilar Market Sustainability
April 16th 2024Magnus Bodin, senior director and head of international access and policy at Biogen, presented warning signs for unsustainable biosimilar markets as well as key factors needed to create effective policies and future-proof biosimilar markets globally.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.